GLP-1 Agonist Solid Forms for Oral Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for type 2 diabetes mellitus (T2DM) and associated cardiometabolic diseases have limited efficacy and are associated with significant side effects, including weight gain, hypoglycemia, and gastrointestinal disturbances.
Innovation Solution
Development of novel solid forms, specifically crystalline and amorphous forms, of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt, which are characterized by unique powder X-ray diffraction, solid-state NMR, and FT-Raman spectroscopy data, and can be administered in pharmaceutical compositions for treating various diseases modulated by GLP-1R.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmacological treatments for T2DM are used, then glucose levels can be controlled, but weight gain and gastrointestinal disturbances occur
Solution Approach 1:
The patent develops novel solid forms (crystalline and amorphous) of a GLP-1R agonist compound, changing the physical and chemical parameters of the drug substance. This includes creating different crystal polymorphs with distinct PXRD patterns, DSC thermograms, and solid-state NMR characteristics, which can improve drug stability, solubility, and bioavailability while maintaining therapeutic efficacy with reduced side effects
Solution Approach 2:
The patent creates composite pharmaceutical formulations containing the novel solid forms of the GLP-1R agonist combined with pharmaceutically acceptable excipients. These composite materials are designed to enhance drug delivery, improve patient compliance through oral administration, and reduce gastrointestinal side effects compared to parenteral formulations
2Reliability
If GLP-1R agonists are administered to treat T2DM and obesity, then metabolic control improves, but administration complexity and patient compliance challenges arise
Solution Approach 1:
The patent transforms the drug from parenteral (injection) form to oral solid dosage forms by developing stable crystalline and amorphous forms that can withstand gastrointestinal conditions. This parameter change in administration route eliminates injection requirements, improving patient compliance and ease of use while maintaining metabolic control efficacy
Solution Approach 2:
The patent replaces the mechanical injection system with an oral pharmaceutical formulation system. The novel solid forms are designed to dissolve and release the active compound in the gastrointestinal tract, substituting the need for subcutaneous injection with a simpler oral administration method that patients can self-administer
3Reliability
If new solid forms of the compound are developed, then stability and bioavailability improve, but manufacturing complexity increases
Solution Approach 1:
The patent performs preliminary characterization of the novel solid forms using PXRD, DSC, TGA, and solid-state NMR to establish quality attributes and processing parameters before scale-up. This preliminary work defines critical material attributes and process parameters that guide manufacturing, reducing complexity during commercial production
Solution Approach 2:
The patent optimizes crystallization and formulation parameters to achieve the desired solid forms with improved stability and bioavailability. By carefully controlling parameters such as solvent composition, temperature, pH, and drying conditions, the patent creates reproducible manufacturing processes that balance product quality with manufacturing feasibility
Data Source
AI summary
The invention provides solid forms of 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt for example, Form 1 or Form 2; as well as pharmaceutical compositions, and the uses thereof in treating diseases, conditions or disorders modulated by GLP-1R in a mammal, such as a human.